HCAP stands for healthcare-associated pneumonia, a classification that was used to describe lung infections in people who had recent contact with the healthcare system but weren’t currently hospitalized. The term was introduced in 2005 guidelines to distinguish these patients from those with standard community-acquired pneumonia (CAP), based on the idea that their exposure to healthcare settings put them at higher risk for drug-resistant bacteria. The classification has since been retired from official guidelines, but the term still appears in medical records, older resources, and clinical conversations.
How HCAP Was Originally Defined
A patient was classified as having HCAP if they developed pneumonia while meeting any one of four criteria: living in a nursing home or long-term care facility, receiving IV antibiotics, chemotherapy, or wound care within the previous 30 days, being hospitalized for two or more days within the previous 90 days, or attending a hospital or hemodialysis clinic. The logic was straightforward. People in these settings are exposed to hospital-grade bacteria that tend to be harder to treat with standard antibiotics. That exposure, the thinking went, meant they needed broader, more aggressive antibiotic therapy from the start.
Why the Classification Was Removed
In 2016, the Infectious Diseases Society of America and the American Thoracic Society dropped HCAP from their updated pneumonia guidelines. The reason was that the category wasn’t working as intended. It cast too wide a net. Many patients who met the HCAP criteria turned out to have ordinary, easy-to-treat bacteria, not drug-resistant ones. MRSA prevalence among HCAP patients ranged from just 0.7% to 30% across studies, and Pseudomonas prevalence ranged from 0.7% to 23%. That’s an enormous spread, meaning the label alone was a poor predictor of which patients actually harbored resistant organisms.
The real problem was what happened when doctors followed the guidelines. A 2013 meta-analysis of over 15,850 patients found that treating HCAP according to the 2005 guidelines was associated with an 80% increase in 30-day mortality compared to not following those guidelines. Patients were receiving unnecessarily broad-spectrum antibiotics, which carried their own risks: side effects, disruption of healthy gut bacteria, and the promotion of further antibiotic resistance. The HCAP label was, in many cases, leading to worse care rather than better care.
Mortality Rates Compared to Standard Pneumonia
Patients classified as HCAP did have higher death rates than those with standard community-acquired pneumonia. Early reports placed HCAP mortality at roughly 20% to 25%, which is closer to what’s seen in hospital-acquired pneumonia than in CAP. Later studies showed a wider range of 5% to 33%, suggesting that the HCAP population was too diverse to treat as a single group. Some patients in this category were genuinely sick with resistant infections, while others simply happened to live in a nursing home and had a straightforward case of pneumonia. Lumping them together obscured these differences.
What Replaced HCAP
Rather than using a broad category based on where someone received care, current approaches focus on individual risk factors for drug-resistant infections. One tool developed for this purpose is the DRIP score (Drug Resistance in Pneumonia), which assigns points based on specific personal risk factors rather than general healthcare exposure. Two factors stand out as the strongest predictors: having a prior infection with a drug-resistant organism (which carries the most weight) and having taken antibiotics within the previous 60 days. A patient with a prior resistant infection was more than ten times as likely to have a drug-resistant pneumonia compared to someone without that history.
This individualized approach lets doctors target broad-spectrum antibiotics at the patients who genuinely need them, while sparing others from unnecessary treatment. At a threshold score of 2 or higher, the DRIP model identified resistant infections with 47% sensitivity and 94% specificity, meaning it rarely flagged patients who didn’t actually have resistant bacteria.
How Pneumonia Is Managed in Nursing Homes Now
Nursing home residents, who made up a large portion of former HCAP patients, are now managed with more nuanced protocols. Key decisions include whether to hospitalize or treat in place, whether to start with IV or oral antibiotics, and when to switch from IV to oral therapy. Providers typically look for signs of clinical stability before making that switch: improving symptoms, being fever-free for at least 16 hours, no serious cardiac or other events in the first two to three days, and the ability to swallow oral medication.
There’s also a growing emphasis on shorter antibiotic courses. Clinical trials have shown that shorter regimens work just as well as traditionally longer ones for common bacterial pneumonia. Many facilities now use an “antibiotic time out” protocol, a scheduled check-in during treatment to reassess whether the current antibiotic is still appropriate or can be stopped. This helps reduce unnecessary antibiotic exposure, which is especially important in long-term care settings where resistant bacteria spread most easily.